Status:

RECRUITING

The Benefits of Hippotherapy for Patients With Parkinson's Disease of 75 Years

Lead Sponsor:

Central Hospital Saint Quentin

Conditions:

Parkinson Disease

Eligibility:

All Genders

75+ years

Phase:

NA

Brief Summary

There is no cure for Parkinson's disease, resulting in an interest for research in this domain. Non pharmacological measures remain essential, specifically physical activity. Hippotherapy is a nonconv...

Detailed Description

Parkinson's disease is a degenerative disorder with a prevalence of 2.50 patients per 1,000 people in 2015. Prevalence and incidence increase progressively with age up to the age of 80; more than half...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Age ≥ 75 years with PD according to Movement Disorders Society criteria (2015).
  • Clinical diagnosis of Alzheimer's disease
  • Has been on stable antiparkinsonian treatment for less than 3 months.
  • Ability to understand the principle of the study as well as its risks.
  • Written consent to participate in the trial.
  • Have social insurance
  • Agree to comply with all safety procedures during the study and its duration.
  • Ability to understand and freely give consent
  • Patient affiliated to social security or entitled beneficiary
  • Autonomy preserved
  • Exclusion criteria :
  • age \<75 years
  • refusal to sign consent
  • MOCA \<23
  • Presence of major behavioural problems that do not allow MRI to be performed under optimal conditions
  • Subjects unable to receive informed information, unable to participate in the study as a whole
  • Subjects with a diagnosis of atypical parkinsonian syndrome (Lewy body disease, progressive supranuclear palsy, multisystem atrophy, cortico-basal degeneration, etc.).
  • A classic contraindication to an MRI examination: claustrophobia, presence of incompatible foreign material,
  • Subjects who have practised horse riding at a high level, animal phobias, wish to stop studying, etc.
  • No affiliation to a social security scheme
  • Antiparkinsonian treatment has not been stable for at least 3 months.
  • People under protective supervision (guardianship, curatorship)
  • People under family guardianship are also excluded, as are people for whom a mandate for future protection has been activated.

Exclusion

    Key Trial Info

    Start Date :

    July 1 2023

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    July 1 2024

    Estimated Enrollment :

    36 Patients enrolled

    Trial Details

    Trial ID

    NCT06500182

    Start Date

    July 1 2023

    End Date

    July 1 2024

    Last Update

    July 17 2024

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Centre Hospitalier de Saint-Quentin;

    Saint-Quentin, Aisne, France, 02100